^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)

    i
    Other names: NTRK2, TRKB, Neurotrophic tyrosine kinase, receptor, type 2
    Apply
    A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer (NAUTIKA1) (NCT04302025)
    Phase 2
    Genentech, Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/06/2020
    Primary completion :
    12/30/2025
    Completion :
    03/06/2029
    PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Cotellic (cobimetinib) • Gavreto (pralsetinib) • divarasib (RG6330)
    A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations (CARE study) (NCT04094610)
    Phase 1/2
    Turning Point Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    03/12/2020
    Primary completion :
    09/30/2026
    Completion :
    09/30/2027
    ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK
    |
    ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion
    |
    Augtyro (repotrectinib)
    A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) (NCT02576431)
    Phase 2
    Bayer
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    09/30/2015
    Primary completion :
    07/20/2025
    Completion :
    10/31/2025
    NTRK1 • NTRK3 • NTRK2
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion
    |
    Vitrakvi (larotrectinib)
    Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body (ON-TRK) (NCT04142437)
    Phase N/A
    Bayer
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    04/03/2020
    Primary completion :
    11/30/2029
    Completion :
    03/31/2030
    NTRK1 • NTRK3 • NTRK2 • NTRK
    |
    NTRK fusion
    |
    Vitrakvi (larotrectinib)
    A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) (NCT03093116)
    Phase 1/2
    Turning Point Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    03/07/2017
    Primary completion :
    02/29/2028
    Completion :
    02/29/2028
    ALK • ROS1 • NTRK1 • NTRK3 • NTRK2
    |
    ROS1 fusion
    |
    Augtyro (repotrectinib) • midazolam hydrochloride
    Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) (NCT04631744)
    Phase 2
    Weill Medical College of Cornell University
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    03/03/2021
    Primary completion :
    07/01/2026
    Completion :
    07/01/2027
    FLT3 • NTRK2 • AXL • KDR • FLT1 • FLT4
    |
    Cabometyx (cabozantinib tablet)
    Feasibility of Bronchial Washing Fluid for Molecular Testing with Next Generation Sequencing in Lung Cancer (NCT06141005)
    Phase N/A
    Pusan National University Hospital
    Active, not recruiting
    Last update posted :
    01/03/2025
    Initiation :
    11/30/2023
    Primary completion :
    08/29/2024
    Completion :
    08/29/2025
    EGFR • HER-2 • ALK • RET • NTRK1 • NTRK3 • NTRK2
    |
    BRAF V600E • KRAS mutation • EGFR mutation • RET mutation • ROS1 fusion
    Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer (NCT05783323)
    Phase 2
    Children's Hospital of Philadelphia
    Recruiting
    Last update posted :
    11/12/2024
    Initiation :
    02/14/2024
    Primary completion :
    10/01/2026
    Completion :
    10/01/2027
    NTRK1 • NTRK3 • NTRK2 • NTRK
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion
    |
    Vitrakvi (larotrectinib)
    Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors (NCT04879121)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    04/30/2021
    Primary completion :
    11/11/2025
    Completion :
    11/11/2025
    NTRK1 • NTRK3 • NTRK2
    |
    Vitrakvi (larotrectinib)
    A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors (NCT05828303)
    Phase 1
    Turning Point Therapeutics, Inc.
    Recruiting
    Last update posted :
    04/11/2024
    Initiation :
    06/28/2024
    Primary completion :
    07/31/2025
    Completion :
    11/30/2025
    ROS1 • NTRK1 • NTRK3 • NTRK2
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion
    |
    Augtyro (repotrectinib) • metformin
    A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients (NCT06010342)
    Phase 2
    Teligene US
    Not yet recruiting
    Last update posted :
    04/10/2024
    Initiation :
    05/01/2024
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    NTRK1 • NTRK3 • NTRK2
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion
    |
    TL118
    Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG) (NCT02650401)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    03/29/2024
    Initiation :
    05/03/2016
    Primary completion :
    06/15/2025
    Completion :
    06/15/2025
    ROS1 • NTRK1 • NTRK3 • NTRK2
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion
    |
    Rozlytrek (entrectinib)